Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurology. 2005 Jun 28;64(12):2029-32. Epub 2005 May 25.

Infant botulism in the age of botulism immune globulin.

Author information

  • 1Division of Pediatric Neurology, Department of Pediatrics, The University of Utah, Primary Children's Medical Center, Salt Lake City, UT, USA. joel.thompson@hsc.utah.edu

Abstract

Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.

PMID:
15917401
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk